The study will evaluate Orgenesis’ novel automated cell culturing system, among other technologies, which is designed to enable faster and safer generation and expansion of tumor-infiltrating lymphocytes (TIL).
The idea is to provide a simplified method for TIL generation and expansion in an automated, controlled system from initial production to final product with minimal human operation, the company said.
READ: Orgenesis launches research collaboration with Madrid hospital to establish point-of-care center
“Partnering with Edith Wolfson Medical Center, an established and well-respected medical institution, to conduct this clinical trial will further validate our cell processing system for TIL generation and expansion,” Orgenesis CEO Vered Caplan said in a statement. “These POCare Technologies are not only highly versatile, but also highly expandable and as a result, could increase our ability to grow various types of cells for a broad range of customer needs.”
The collaboration is part of Orgenesis’ larger goal of developing new approaches to immune-oncology through its CGT Biotech Platform, Caplan said. The company plans to deploy any such solutions across its POCare Network, which consists of a growing number of medical institutions around the world, including a recently announced collaboration with Hospital Infantil Universitario Niño Jesús in Madrid.
“We look forward to collaborating with Orgenesis on this important clinical trial to advance and validate this breakthrough Orgenesis proprietary TILs technology, with the joint goal of reducing manufacturing costs and bringing new, cell and gene therapy products to cancer patients worldwide,” said Ronen Brenner, head of The Edith Wolfson Medical Center’s oncology division.
The Edith Wolfson Medical Center is a public hospital founded in 1980 and located
Orgenesis, based in Germantown, Maryland, is focused on accelerating the commercialization of transforming the delivery of cell and gene therapies while also lowering costs.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel